Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan
· Delayed Price · Currency is TWD 75.40
-1.90 (-2.46%)
Apr 29, 2026, 1:30 PM CST
Gongwin Biopharm Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 36.45 | 32.04 | 18.92 | 1.14 | 1.14 | Upgrade
|
| Revenue Growth (YoY) | 13.75% | 69.39% | 1554.86% | - | 37.21% | Upgrade
|
| Cost of Revenue | 10.36 | 23.36 | 7.72 | 0.08 | 0.07 | Upgrade
|
| Gross Profit | 26.09 | 8.68 | 11.2 | 1.07 | 1.08 | Upgrade
|
| Selling, General & Admin | 115.55 | 101.56 | 91.88 | 67.43 | 38.85 | Upgrade
|
| Research & Development | 119.47 | 63.27 | 52.65 | 194.32 | 83.05 | Upgrade
|
| Operating Expenses | 233.38 | 170.74 | 144.53 | 261.75 | 121.9 | Upgrade
|
| Operating Income | -207.29 | -162.06 | -133.33 | -260.68 | -120.83 | Upgrade
|
| Interest Expense | -5.15 | -4.3 | -7.19 | -3.19 | -1.18 | Upgrade
|
| Interest & Investment Income | 70.81 | 64.62 | 41.61 | 6.82 | 2.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.46 | -4.69 | -4.85 | -39.6 | 0.9 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.09 | 3.47 | 2.58 | 4.51 | 2.05 | Upgrade
|
| EBT Excluding Unusual Items | -140 | -102.96 | -101.18 | -292.13 | -116.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | 19.21 | 11.11 | - | - | 0.74 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.08 | -0 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.2 | Upgrade
|
| Pretax Income | -120.87 | -91.86 | -101.18 | -292.13 | -114.72 | Upgrade
|
| Income Tax Expense | 0.16 | 0.13 | - | - | 15.2 | Upgrade
|
| Earnings From Continuing Operations | -121.03 | -91.99 | -101.18 | -292.13 | -129.92 | Upgrade
|
| Minority Interest in Earnings | 6.9 | 9.44 | 9.14 | - | 8.34 | Upgrade
|
| Net Income | -114.13 | -82.55 | -92.04 | -292.13 | -121.58 | Upgrade
|
| Net Income to Common | -114.13 | -82.55 | -92.04 | -292.13 | -121.58 | Upgrade
|
| Shares Outstanding (Basic) | 123 | 121 | 113 | 111 | 110 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 121 | 113 | 111 | 110 | Upgrade
|
| Shares Change (YoY) | 2.19% | 6.64% | 1.92% | 1.44% | 4.87% | Upgrade
|
| EPS (Basic) | -0.92 | -0.68 | -0.81 | -2.63 | -1.11 | Upgrade
|
| EPS (Diluted) | -0.92 | -0.68 | -0.81 | -2.63 | -1.11 | Upgrade
|
| Free Cash Flow | -137.62 | -293.3 | -111.7 | -239.54 | -218.52 | Upgrade
|
| Free Cash Flow Per Share | -1.11 | -2.43 | -0.99 | -2.15 | -2.00 | Upgrade
|
| Gross Margin | 71.58% | 27.09% | 59.21% | 93.26% | 94.31% | Upgrade
|
| Operating Margin | -568.76% | -505.80% | -704.87% | -22806.74% | -10570.95% | Upgrade
|
| Profit Margin | -313.14% | -257.64% | -486.58% | -25558.44% | -10637.01% | Upgrade
|
| Free Cash Flow Margin | -377.59% | -915.41% | -590.55% | -20956.69% | -19118.11% | Upgrade
|
| EBITDA | -198.59 | -153.87 | -125.03 | -252.2 | -112.82 | Upgrade
|
| D&A For EBITDA | 8.7 | 8.19 | 8.29 | 8.48 | 8 | Upgrade
|
| EBIT | -207.29 | -162.06 | -133.33 | -260.68 | -120.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.